Holen Sie sich die Stockscreener-App
7.13
4.30%
-0.32
Handel nachbörslich:
7.10
-0.03
-0.42%
Schlusskurs vom Vortag:
$7.45
Offen:
$7.44
24-Stunden-Volumen:
5.31M
Relative Volume:
0.98
Marktkapitalisierung:
$1.85B
Einnahmen:
$6.28B
Nettoeinkommen (Verlust:
$700.00M
KGV:
2.6484
EPS:
2.6922
Netto-Cashflow:
$537.00M
1W Leistung:
-6.43%
1M Leistung:
-22.84%
6M Leistung:
-18.61%
1J Leistung:
-51.60%
1-Tages-Spanne:
$7.05
$7.52
1-Wochen-Bereich:
$7.05
$7.88
52-Wochen-Spanne:
$6.18
$17.23
Organon Co Stock (OGN) Company Profile
Firmenname
Organon Co
Sektor
Telefon
551-430-6000
Adresse
30 HUDSON STREET, JERSEY CITY
Vergleichen Sie OGN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OGN
Organon Co
|
7.13 | 1.94B | 6.28B | 700.00M | 537.00M | 2.6922 |
|
LLY
Lilly Eli Co
|
1,043.29 | 939.41B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
203.07 | 487.91B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
229.45 | 411.64B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
124.36 | 244.28B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
94.97 | 235.92B | 63.90B | 19.05B | 13.05B | 7.5596 |
Organon Co Stock (OGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-27 | Herabstufung | Piper Sandler | Overweight → Underweight |
| 2025-05-02 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2024-09-06 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2023-11-03 | Herabstufung | Goldman | Buy → Neutral |
| 2023-09-21 | Eingeleitet | Barclays | Overweight |
| 2023-03-16 | Eingeleitet | Raymond James | Outperform |
| 2022-10-14 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-09-06 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-08-05 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-04-27 | Eingeleitet | Goldman | Buy |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2021-10-07 | Eingeleitet | Piper Sandler | Neutral |
| 2021-09-01 | Eingeleitet | BofA Securities | Buy |
| 2021-07-22 | Eingeleitet | Citigroup | Buy |
| 2021-06-15 | Eingeleitet | JP Morgan | Neutral |
| 2021-06-11 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2021-06-10 | Eingeleitet | Evercore ISI | Outperform |
Alle ansehen
Organon Co Aktie (OGN) Neueste Nachrichten
Co. (7XP) stock profit from AI boomChart Signals & Consistent Profit Alerts - newser.com
Discipline and Rules-Based Execution in OGN Response - news.stocktradersdaily.com
Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know - sharewise.com
Henlius, Organon win US FDA approval of first Perjeta biosimilar - BioWorld MedTech
Co. (7XP) stock profit from automation waveWeekly Trade Recap & Fast Gain Swing Alerts - newser.com
Organon Executive Chairman of the Board Acquires 525% More Stock - simplywall.st
Read This Before Considering Organon & Co. (NYSE:OGN) For Its Upcoming US$0.02 Dividend - Yahoo Finance
Global Contraceptive Devices Market is Set to Accelerate at a CAGR of ~6% by 2032, as Demand for Advanced Birth Control Solutions Rises | DelveInsight - GlobeNewswire Inc.
Organon, Shanghai Henlius Biotech Says FDA Clears Poherdy as Pertuzumab Biosimilar - MarketScreener
The 5 Most Interesting Analyst Questions From Organon’s Q3 Earnings Call - The Globe and Mail
Henlius, Organon (NYSE: OGN) Win FDA Approval for POHERDY, First Pertuzumab Biosimilar - Stock Titan
The 5 Most Interesting Analyst Questions From Organon's Q3 Earnings Call - Finviz
Organon Q3 2025 Earnings: Revenue & EPS Beat EstimatesNews and Statistics - IndexBox
Organon (OGN) Price Target Decreased by 10.77% to 9.86 - Nasdaq
Are Margin Pressures Reshaping Organon’s (OGN) Long-Term Competitive Position? - simplywall.st
Organon & Co. (OGN) Stock Price | Live Quotes & Charts | NYSE - StocksToTrade
Organon Investigation Initiated By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates Claims On Behalf of Investors of Organon & Co.OGN - Business Wire
Earnings Release: Here's Why Analysts Cut Their Organon & Co. (NYSE:OGN) Price Target To US$9.67 - simplywall.st
Executive Chairman of the Board of Organon Carrie Cox Buys 525% More Shares - Yahoo Finance
First Perjeta Biosimilar Is Approved In The US For Henlius And Organon - Citeline News & Insights
Executive Chair Makes Bold Move with Major Organon Stock Purchase - TipRanks
Organon Shares Face Mounting Pressure Amid Strategic Shifts - AD HOC NEWS
Laborie to acquire Organon’s JADA System for $465M - NJBIZ
Bank of America Securities Sticks to Its Sell Rating for Organon (OGN) - The Globe and Mail
Organon (OGN): Assessing Valuation After Recent Share Price Rebound - Yahoo Finance
Organon (OGN) Stock Trades Down, Here Is Why - The Globe and Mail
Is Organon’s 15% Share Price Jump a Sign of Real Value in 2025? - Yahoo Finance
Organon & Co. Earnings Call: Mixed Results Amid Challenges - TipRanks
JP Morgan Lowers Price Target for Organon (OGN) to $12.00 | OGN Stock News - GuruFocus
Organon & Co. (OGN) Climbs 13.7% Ahead of Dividends - Insider Monkey
Organon: Q3 Earnings Lift Struggling StockBut Not For Long, I Suspect (NYSE:OGN) - Seeking Alpha
Organon Co earnings beat by $0.07, revenue topped estimates - Investing.com Philippines
Organon Analysts Cut Their Forecasts Following Q3 Results - Benzinga
Organon lowers 2025 revenue guidance to $6.2B–$6.25B amid U.S. Nexplanon headwinds and Jada divestiture - MSN
Organon & Co. (NYSE:OGN) Q3 2025 Earnings Call Transcript - MSN
Organon (OGN) Analyst Rating Update: Morgan Stanley Lowers Price Target | OGN Stock News - GuruFocus
Morgan Stanley Maintains Organon & Co(OGN.US) With Hold Rating, Cuts Target Price to $9 - 富途牛牛
Organon price target lowered to $9 from $10 at Morgan Stanley - TipRanks
Organon & Co (OGN) Q3 2025 Earnings Call Highlights: Strong Biosimilars Performance Amidst ... By GuruFocus - Investing.com Canada
Earnings call transcript: Organon Q3 2025 beats forecasts, stock surges By Investing.com - Investing.com Philippines
Organon to divest its JADA® System for USD 465M to Laborie - Medical Buyer
Organon Reports Results for the Third Quarter Ended September 30, 2025 - BioSpace
OGN Q3 2025 Deep Dive: Leadership Changes, Portfolio Shifts, and Guidance Recalibration - Yahoo Finance
Decoding Organon & Co (OGN): A Strategic SWOT Insight - GuruFocus
Organon & Co. Reports Modest Q3 Revenue Growth - TipRanks
Organon (OGN) Q3 Earnings and Revenues Beat Estimates - sharewise.com
Organon: Q3 Earnings Snapshot - Chron
[Form 4] Organon & Co. Insider Trading Activity - Stock Titan
Officer Arjona Ferreira Acquires 4,139 Of Organon & Co [OGN] - TradingView
Organon to sell Jada postpartum haemorrhage device - FemTech World
Organon & Co.: Is It Time to Buy or Watch? - StocksToTrade
Finanzdaten der Organon Co-Aktie (OGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.33%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):